Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
Ratings actions from Benzinga: GMT) Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan StanleyRatings actions from Benzinga
Ratings actions from Benzinga: GMT) Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan StanleyRatings actions from Benzinga